- $48.67m
- $129.31m
- $83.81m
Brief: Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer
Brief: Carlyle, SK Capital Partners And Bluebird Bio Provide Updated Tender Instructions
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Robinhood, Oklo, Chimera Investment
U.S. STOCKS ON THE MOVE-AbbVie, Millrose Properties, European Wax Center
Deals of the day-Mergers and acquisitions
Bluebird bio receives higher upfront offer from PE firms Carlyle, SK Capital (updated)
bluebird bio soars on revised offer from Carlyle, SK Capital Partners
Bluebird bio receives higher upfront offer from PE firms Carlyle, SK Capital
Brief: Carlyle says Bluebird stockholders can elect $3 per share plus cvr or $5 per share
Brief: Carlyle And Sk Capital Receive All Required Regulatory Approvals To Complete The Acquisition Of Bluebird Bio
bluebird bio Inc expected to post a loss of $3.69 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Grocery Outlet, Abbott, General Dynamics
U.S. STOCKS ON THE MOVE-Lyft, Hertz Global, Prologis
U.S. STOCKS ON THE MOVE-Tesla, Cal-Maine Foods, Bluebird Bio
Bluebird Bio falls after Ayrmid fails to give binding offer
Brief: Bluebird Bio Confirms That Ayrmid, Has Not Delivered A Binding Offer Or Obtained Necessary Financing Despite Extensive Engagement
Brief: Xcellbio Granted Bluebird Bio Commercial License, Got Into Supply Agreement For Use Of Co's Proprietary Cell Manufacturing Technology, Avatar
U.S. STOCKS ON THE MOVE-Veritex, Gaming and Leisure Properties, Apple